PHARMACY

Sandoz launches two products

BY Alaric DeArment

PRINCETON, N.J. The generics arm of drug maker Novartis has launched two new products.

Sandoz announced the launch of topiramate sprinkle capsules, a generic version of Johnson & Johnson’s epilepsy drug Topamax Sprinkle, and calcium acetate capsules, an authorized generic of Fresenius Medical Care’s kidney failure drug PhosLo.

Topiramate capsules had sales of $56 million during the 12-month period ending in August, and PhosLo had sales of $42 million during the same period, according to IMS Health data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Actress Olympia Dukakis, husband to appear in diabetes ads

BY Alaric DeArment

NEW YORK Passengers in New York taxis and viewers watching CNN at the airport will see actress Olympia Dukakis and her husband, Louis Zorich, talking about diabetes.

The appearance of the two actors won’t be in a movie, but in a public service announcement that’s part of drug maker Novo Nordisk’s “Ask. Screen. Know.” campaign to encourage diabetes awareness among the elderly.

The ad directs viewers to the Web site www.askscreenknow.com, which allows them to send voicemails and emails under Dukakis’ name encouraging them to undergo diabetes screenings paid for by Medicare.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves generic epilepsy treatment

BY Alaric DeArment

PITTSBURGH Generic drug maker Mylan has received the Food and Drug Administration’s approval for its version of a drug used to treat epilepsy.

Mylan announced Thursday the approval of its topiramate sprinkle capsules in the 15-mg and 25-mg strengths. The capsules are designed to be opened and sprinkled onto soft food and are a generic version of Johnson & Johnson’s Topamax Sprinkle Capsules.

The branded version of the drug had sales of $58 million for the 12-month period ended June 30, according to IMS Health data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?